Table 2 |
|||
|
Association between BP1 mRNA expression and clinicopathological data |
|||
| BP1 mRNA |
|||
|
|
|||
| Factors |
Negative |
Positive |
P |
|
|
|||
| Age |
1.00 |
||
| Premenopausal |
2 (17%) |
10 (83%) |
|
| (<50 years) |
|||
| Postmenopausal |
7 (21%) |
26 (79%) |
|
| (≥ 50 years) |
|||
| Tumor size |
1.00 |
||
| <2.0 cm |
1 (17%) |
5 (83%) |
|
| ≥ 2.0 cm |
7 (19%) |
30 (81%) |
|
| Lymph node metastasis |
1.00 |
||
| Negative |
4 (20%) |
16 (80%) |
|
| Positive |
4 (18%) |
18 (82%) |
|
| Histologic grade |
0.29 |
||
| I |
1 (20%) |
4 (80%) |
|
| II |
4 (27%) |
11 (73%) |
|
| III |
2 (9%) |
20 (91%) |
|
| ER status |
0.03 |
||
| Negative |
0 (0%) |
18 (100%) |
|
| Positive |
7 (27%) |
19 (73%) |
|
| PR status |
0.02 |
||
| Negative |
1 (4.0%) |
24 (96%) |
|
| Positive |
6 (33%) |
12 (67%) |
|
| Race |
0.04 |
||
| Caucasian |
6 (43%) |
8 (57%) |
|
| African American |
3 (11%) |
25 (89%) |
|
|
|
|||
|
ER, estrogen receptor; PR, progesterone receptor. Data were unavailable or indeterminate for parameters as follows: age (one tumor), tumor size (three tumors), lymph node metastasis (four tumors), histologic grade (four tumors), ER status (two tumors), PR status (three tumors), and race (four tumors). |
|||
|
Fu et al. Breast Cancer Res 2003 5:R82 doi:10.1186/bcr602 |
|||
